‹ Back to document
Comment from The 3Rs Collaborative
Anonymous
Analysis pending
See attached file
Attachments
2026_3RsC_FDA_Oncology Pharma Streamlining Safety for Biologics etc. (PDF)
View on Regulations.gov →